WallStSmart

Palladyne AI Corp (PDYN)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 4835% more annual revenue ($258.90M vs $5.25M). PDYN leads profitability with a 191.4% profit margin vs -15.5%. PDYN earns a higher WallStSmart Score of 45/100 (D).

PDYN

Hold

45

out of 100

Grade: D

Growth: 5.3Profit: 6.0Value: 5.3Quality: 6.5
Piotroski: 3/9Altman Z: -13.21

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for PDYN.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PDYN4 strengths · Avg: 9.8/10
Return on EquityProfitability
30.8%10/10

Every $100 of equity generates 31 in profit

Profit MarginProfitability
191.4%10/10

Keeps 191 of every $100 in revenue as profit

Revenue GrowthGrowth
118.3%10/10

Revenue surging 118.3% year-over-year

Debt/EquityHealth
0.209/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

PDYN4 concerns · Avg: 3.5/10
P/E RatioValuation
25.7x4/10

Moderate valuation

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$291.02M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : PDYN

The strongest argument for PDYN centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 191.4% and operating margin at -561.0%. Revenue growth of 118.3% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : PDYN

The primary concerns for PDYN are P/E Ratio, EPS Growth, Market Cap.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

PDYN profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

PDYN carries more volatility with a beta of 3.75 — expect wider price swings.

PDYN is growing revenue faster at 118.3% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PDYN scores higher overall (45/100 vs 41/100), backed by strong 191.4% margins and 118.3% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Palladyne AI Corp

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Palladyne AI Corp. The company is headquartered in Salt Lake City, Utah.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?